Introduction: Cases of lesions that simulate Bowen’s disease have been previously described in the literature. Case Report: Nine exophytic verruca-like lesions with histological findings of Bowen’s disease (BD) are described. All cases had a rapid growth, and were located on the face and neck of elderly patients with chronic solar skin damage. We carried out p16 immunohistochemical staining using the immunoperoxidase technique, which was negative in all cases. Discussion: We think that these 9 lesions are only histologically mimicking BD, and could be a subtype of verruca (‘bowenoid wart’). These lesions could be provoked by nononcogenic human papillomavirus (HPV), as in other cases previously described. The p16 staining was negative in all cases, in contrast with most BD cases. It would be interesting to study whether positive p16 staining is related to oncogenic HPV, whereas negative p16 staining could be associated with low or nononcogenic HPV; thus, more studies are needed.

Kossard S, Rosen R: Cutaneous Bowen’s disease: an analysis of 1,001 cases according to age, sex and site. J Am Acad Dermatol 1992;27:406–410.
Clavel CE, Pham-Huu V, Durlach AP, Birembaut PL, Bernard PM, Derancourt CG: Mucosal oncogenic human papillomaviruses and extragenital Bowen’s disease. Cancer 1999;86:282–287.
Zheng S, Adachi A, Shimizu M, Shibata SI, Yasue S, Sakakibara A, et al: Human papillomaviruses of the mucosal type are present in some cases of extragenital Bowen’s disease. Br J Dermatol 2005;152:1243–1247.
Quereux G, N’Guyen JM, Dreno B: Human papillomavirus and extragenital in situ carcinoma. Dermatology 2004;209:40–45.
Fitzgerald DA: Cancer precursors. Semin Cutan Med Surg 1998;17:108–113.
Martínez S, del Boz J, Vera A, Sanz A, Crespo V: Spindle-cell carcinoma in situ treated with 5% imiquimod. Actas Dermosifiliogr 2006;97:267–270.
Strayer DS, Santa-Cruz DJ: Carcinoma in situ of the skin: a review of histopathology. J Cutan Pathol 1980;7:244–259.
Hodges A, Smoller BR: Immunohistochemical comparison of p16 expression in actinic keratoses and squamous cell carcinomas of the skin. Mod Pathol 2002;15:1121–1125.
Soufir N, Moles JP, Vilmer C, Moch C, Verola O, Rivet J, et al: P16 UV mutations in human skin epithelial tumors. Oncogene 1999;18:5477–5481.
Conscience I, Jovenin N, Coissard C, Lorenzato M, Durlach A, Grange F, et al: P16 is overexpressed in cutaneous carcinomas located on sun-exposed areas. Eur J Dermatol 2006;16:518–522.
Masumoto N, Fujii T, Ishikawa M, et al: P16 overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix. Human Pathol 2003;34:778–783.
Zielinski GD, Snijders PJ, Rozendaal L, et al: The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol 2003;201:535–543.
Santos M, Landolfi S, Olivella A, Lloveras B, Klaustermeier J, Suarez H, et al: P16 overexpression identifies HPV-positive vulvar squamous cell carcinomas. Am J Surg Pathol 2006;30:1347–1356.
Salama ME, Mahmood MN, Qureshi HS, et al: p16INK4a expression in actinic keratosis and Bowen’s disease. Br J Dermatol 2003;149:1006–1012.
Auepemkiate S, Thongsuksai P, Boonyaphiphat P: P16 (INK4A) expression in Bowen’s disease and bowenoid papulosis. J Med Assoc Thai 2006;89:1460–1465.
Antoniou C, Kosmadaki MG, Stratigos AJ, Katsambas AD: Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy. Dermatology 2008;216:364–365.
Weedon D: Skin Pathology. New York, Churchill Livingstone, 1998, pp 583–603.
Inaba Y, Egawa K, Yoshimura K, Ono T: Demonstration of human papillomavirus type I DNA in a wart with bowenoid histologic changes. Am J Dermatopathol 1993;15:172–175.
Goette DK: Carcinoma in situ in verruca vulgaris. Int J Dermatol 1980;19:98–101.
Baer RL, Garcia RL, Partsalidou V, Ackerman AB: Papillated squamous cell carcinoma in situ arising in a seborrheic keratosis. J Am Acad Dermatol 1981;5:561–565.
Monteagudo JC, Jorda E, Terencio C, Llombart-Bosch A: Squamous cell carcinoma in situ (Bowen’s disease) arising in seborrheic keratosis: three lesions in two patients. J Cutan Pathol 1989;16:348–352.
Marschall SF, Ronan SG, Massa MC: Pigmented Bowen’s disease arising from pigmented seborrheic keratoses. J Am Acad Dermatol 1990;23:440–444.
Bloch PH: Transformation of seborrheic keratosis into Bowen’s disease. J Cutan Pathol 1978;5:361–367.
Gallimore AP: Malignant transformation of a clonal seborrheic keratosis. Br J Dermatol 1991;124:287–290.
Sun JD, Barr RJ: Papillated Bowen disease, a distinct variant. Am J Dermatopathol 2006;28:395–398.
Brufau Redondo C: Precáncer epitelial cutáneo-mucoso; in Herrera Ceballos E (ed): Tumores Cutáneos. Madrid, Grupo Aula Médica, 1999, pp 97–116.
Harwood CA, Proby CM: Human papillomaviruses and non-melanoma skin cancer. Curr Opin Infect Dis 2002;15:101–114.
Corbalan-Velez R, Ruiz-Macia JA, Brufau C, Carapeto FJ: Cutaneous squamous cell carcinoma and human papillomavirus. Actas Dermosifiliogr 2007;98:583–593.
Murao K, Kubo Y, Takiwaki H, Arase S, Matsumoto K: Bowen’s disease on the sole: p16INK4a overexpression associated with human papillomavirus type 16. Br J Dermatol 2005;152:170–173.
Liu H, Urabe K, Moroi Y, Yasumoto S, Kokuba H, Imafuku S, et al: Expression of p16 and hTERT protein is associated with the presence of high-risk human papillomavirus in bowenoid papulosis. J Cutan Pathol 2006;33:551–558.
Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T: Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153:1741–1748.
Mosher RE, Lee KR, Trivijitsilp P, Crum CP: Cytologic correlates of papillary immature metaplasia (immature condyloma) of the cervix. Diagn Cytopathol 1998;18:16–21.
Wilman JH, Heinz D, Golitz LE, Shroyer KR: Correlation of p16 and pRb expression with HPV detection in Bowen’s disease. J Cutan Pathol 2006;33:629–633.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.